Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Teams With Lycera In Second Autoimmune Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The Michigan-based biotech says the latest discovery and development deal with Merck is validation of its ongoing work with the Big Pharma in the field of autoimmune diseases.

You may also be interested in...



Emerging Markets Earnings Roundup: Merck, Pfizer And Amgen (Part 3)

Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.

Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

Lycera Corp.

Lycera Corp. develops small-molecule immunomodulators. Its lead benzodiazapene-based compounds have shown efficacy in animal models of lupus, psoriasis, rheumatoid arthritis, inflammatory bowel disease and transplant rejection. Lycera also recently acquired a program targeting the TH17 pathway, which controls production of IL-17, a pro-inflammatory cytokine increasingly considered critical to inflammation and autoimmune disease.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel